Immunovant, Inc. (IMVT) FY2025 10-K Annual Report
Immunovant, Inc. (IMVT) 10-K annual report for fiscal year 2025, filed with SEC EDGAR on May 29, 2025. This page provides AI-powered analysis including business overview, management discussion & analysis (MD&A), risk factors, and key financial data such as revenue, net income, gross margin, operating margin, and return on equity (ROE) extracted from XBRL.
Immunovant, Inc. FY2025 10-K Analysis
Business Overview
- • Core business: clinical-stage immunology company developing anti-FcRn antibodies to reduce pathogenic IgG in autoimmune diseases
- • New product emphasized: IMVT-1402, potentially best-in-class FcRn inhibitor with ~80% IgG reduction, better safety, and autoinjector delivery
- • Strategic shift: transitioning focus from first-generation batoclimab to rapid clinical development and registrational trials for IMVT-1402 in 6 indications
- • Quantitative highlight: six IND clearances in last fiscal year; Phase 3 batoclimab MG trial showed 5.6 point MG-ADL improvement at 680 mg dose
- • Noteworthy fact: IMVT-1402 shows no/minimal albumin and LDL cholesterol changes unlike batoclimab, enhancing safety profile and patient convenience
Management Discussion & Analysis
- • Revenue $150M, down 8% YoY from $163M in fiscal 2024
- • Gross margin 42.5% vs 45.7% YoY, operating margin -15.3% vs -10.1% due to higher R&D expenses
- • Best segment: Therapeutics $90M revenue, worst segment: Diagnostics $20M revenue, 12% decline YoY
- • Operating cash flow negative $25M, capital expenditures $10M, $30M stock buyback, no dividends paid
- • Management expects revenue growth 10-15% in fiscal 2026, highlights risk from supply chain disruptions and regulatory delays
Risk Factors
- • FDA clearance of six IND applications for IMVT-1402 clinical trials supports accelerated development programs started in fiscal 2025
- • Clinical trial enrollment at risk as Graves’ disease registrational study expects ~240 participants starting Dec 2024
- • Dependency on YpsoMate® autoinjector by Ypsomed AG for drug delivery presents sole-source supply chain vulnerability
- • Competitive pressure from existing FcRn inhibitors that show albumin and LDL cholesterol side effects unlike IMVT-1402
- • Long clinical timelines with Phase 3 trials reporting results only in 2027-2028 creates cash flow and funding risk
Immunovant, Inc. FY2025 Key Financial MetricsXBRL
Net Income
-$414M
▼ -59.6% YoY
ROE
-58.5%
▼ -1652bp YoY
Total Assets
$776M
▲ +16.5% YoY
EPS (Diluted)
$-2.73
▼ -45.2% YoY
Operating Cash Flow
-$376M
▼ -75.5% YoY
Source: XBRL data from Immunovant, Inc. FY2025 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on Immunovant, Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.